Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.
- DOI
- 10.1182/bloodadvances.2025019368
- Published
- 2026 Sep 8
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2025019368,
title = {Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.},
author = {Sheth S and Lal A and Appiah-Kubi A and Peslak SA and Toiber Temin N and Chen MA and Coates T},
year = {2026},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2025019368},
url = {https://doi.org/10.1182/bloodadvances.2025019368}
}RIS
TY - JOUR TI - Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias. AU - Sheth S AU - Lal A AU - Appiah-Kubi A AU - Peslak SA AU - Toiber Temin N AU - Chen MA AU - Coates T PY - 2026 JO - Blood advances DO - 10.1182/bloodadvances.2025019368 UR - https://doi.org/10.1182/bloodadvances.2025019368 ER -
APA
S, S., A, L., A, A., SA, P., N, T. T., MA, C., & T, C. (2026). Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias.. Blood advances. https://doi.org/10.1182/bloodadvances.2025019368
Source records
- pubmed · retrieved 2026-09-26T08:55:45.171Z